Survodutide phase 3 SYNCHRONIZE-1 published: up to 16.6% weight loss at 76 weeks

Full results of Boehringer Ingelheim's SYNCHRONIZE-1 trial of survodutide, a once-weekly glucagon and GLP-1 dual agonist, were presented at the ADA meeting and published in the New England Journal of Medicine. Among 725 adults with obesity without diabetes, weight loss at 76 weeks reached up to 16.6% in people who stayed on treatment versus 3.2% on placebo, or about 13% versus 5% regardless of adherence. Gastrointestinal side effects were common, affecting 90% of the 6.0 mg group versus 48% on placebo.